Local advanced lung squamous cell carcinoma
Conditions
Interventions
experimental group:radiotherapy, EP regimen combined with glycididazole sodium (Shimena)
control group: radiotherapy combined with EP regimen
Sponsors
Liaoning Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Locally advanced SCC that is pathologically confirmed (bronchoscopy, mediastinoscopy, CT-guided puncture or supraclavicular lymph nodes) surgically inoperable or patient refused surgery; 2. There are measurable lesions, aged 18 to 75 years, gender is not limited, weight loss is less than 10% within 6 months, can tolerate radiotherapy; 3. The expected life expectancy is 12 months; 4. The subject has no major organ dysfunction, blood routine, liver, kidney function and cardiac function are basically normal; 5. Physical condition WHO score 0~2 points; 6. Laboratory test indicators must meet the following requirements: blood: leukocytes > 4.0 x 10^9 / L, neutrophils more than 5 x 10^9 / L, PLT > 100 x 10^9 / L, hemoglobin > 95g / L. Liver function: TB = 1L and > 40% of normal people corresponding values; 8. The number of cycles of chemotherapy has not exceeded 4; 9. Can understand the situation of this study and sign an informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients who received systemic chemotherapy for more than 5 cycles before enrollment (4 cycles are still eligible for enrollment). 2. History of malignant tumors in other areas, excluding curable non-melanoma skin cancer and cervical carcinoma in situ. 3. Pregnancy and lactation patients. 4. There is currently an infection, but the infection can be controlled after admission. 5. Uncontrollable diabetes - an optional blood glucose > 200mg% (mmmol / L), but if the patient's blood glucose > 200mg%, fasting blood glucose < 140mg% (9.17mmol / L), the patient can be included; 6. Liver and kidney dysfunction; 7. Other serious diseases, such as myocardial infarction within 6 months; 8. People with a history of mental illness that is difficult to control; 9. The investigator believes that it is not appropriate to participate in this trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Tumor SUVmax;Hypoxic zone;Radiotherapy dose; | — |
Secondary
| Measure | Time frame |
|---|---|
| Tumor volume;Tumor withdrawal rate; | — |
Countries
China
Contacts
Public ContactTianlu Wang
Liaoning Cancer Hospital
Outcome results
None listed